Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status:
Unknown status
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
Because of the advantageous activity against VEGF-C and FGF pathways and favorable toxicity
profile comparing with sunitinib, the investigators plan this phase II trial of pazopanib in
cisplatin-refractory recurrent or metastatic HNSCC.